The FDA approved the IL-4/IL-13 inhibitor March 28 in a win for Sanofi and Regeneron. The companies set the biologic's price at $37,000 per year, which is lower than many biologics on the market for psoriasis.
Erytech's lead therapy has shown strong anti-cancer activity in pancreatic cancer, on top of the hematological indications it is already targeting in late-stage trials, spelling good news for the French firm to pursue more studies in other oncology indications such as ovarian cancer.
Starboard has been trying to replace Depomed management and add its own members to the specialty pharma company's board since at least April 2016. This is the investor's second settlement with the pain and neurology specialist.
A key goal of Bristol's second major academic research collaboration is to get trials up-and-running more quickly.
Recent Tweets from Scrip
Tweets from https://twitter.com/IBI_Tweets/lists/scrip-tweets
Commercial Explore this Topic
BioLineRx buys Agalimmune and its alpha Gal candidate for melanoma and possibly other oncology indications. Japan's Ono signs an R&D agreement with Switzerland's Numab, while Boston biotechs Vedantra and Neon will collaborate on potential cancer vaccines.
Targeting the age-dependent decline in immune function is the aim of a new PureTech Health subsidiary, resTORbio, that has licensed two clinical-stage mTORC1 inhibitors from Novartis.
Latest From Commercial
Astellas has joined the growing ranks of research-based pharma firms offloading their older products in Japan, amid rising pricing and generic pressures and an increasing desire to focus on innovation.
La Jolla Pharmaceutical grossed $125m, Inspyr Therapeutics signs a deal to raise up to $100m, Ionis's Akcea makes $100m IPO plans, and $64m in cash for SutroVax tops recent venture capital rounds.
The rare disease specialist’s new CEO is former Baxalta CEO Ludwig Hantson, who takes over the helm immediately after a leadership shakeup coinciding with an audit investigation.
In another vote of confidence in one of its newer respiratory assets, AstraZeneca is extending to Asia its already broad rights to benralizumab, adding to a deal it already has with Kyowa Hakko Kirin for Japan.
While details are scant, the five-year collaboration will pair C4's targeted protein degradation approach with Calico's focus on diseases of aging. Privately held C4 otherwise is aiming to bring its first Degronomid candidate into the clinic in 2018.
Merck & Co and Bristol Myers Squibb's rival anti-PD1 products continue their game of one-upmanship with each gaining a new indication in the latest round of EU CHMP opinions.
Policy & Regulation Explore this Topic
Tesaro takes opportunity of broad approval for Zejula (niraparib) in recurrent ovarian cancer to highlight franchise expansion opportunities in other tumor types, including PD-1 inhibitor combination studies.
With oral naldemedine joining Purdue's pain portfolio, the company will look for ways to foster communication between patients and doctors about treatment for opioid-induced constipation.
Pfizer CEO Ian Read explains why industry has stayed on the sidelines during the current health reform debate and defends drug pricing practices during a speech to the National Press Club.
Pfizer got Bavencio to market by focusing on an unmet need, but the PD-L1 inhibitor is still a few years behind, competing with other checkpoint inhibitors over more valuable indications.
Research & Development Explore this Topic
With the commercial opportunity in the myelofibrosis market expected to double to over $1bn in the next five years, competition to Incyte/Novartis's Jakafi seems further away than ever as CTI BioPharma pulls the European regulatory filing for pacritinib.
Latest From Research & Development
Newron has reported positive Phase IIa data for schizophrenia drug evenamide but Phase III will be critical for the add-on therapy to demonstrate a more robust treatment effect to justify its use on top current treatments.
Xenon Pharmaceuticals' attempts to treat acne with a SCD-1 inhibitor have met with failure at the Phase II stage, casting doubt on the therapeutic strategy and wiping more than 50% of the company's share price.
After a positive outcome from a US Phase I study, South Korea's Sumagen is stepping closer to the launch of the world's first killed-whole HIV vaccine with potential to both prevent and treat AIDS.
You must sign in to use this functionality.
Please Sign In
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with active subscriptions will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.